1st patient enrolled in WIND-PSC natural history study
The first patient has been enrolled in WIND-PSC, a global study to track the natural course of primary sclerosing cholangitis (PSC) and generate real-world…
Cholangitis
Ocaliva shown to reduce markers of liver damage, scarring in PBC trial
Treatment with Ocaliva (obeticholic acid) — an oral therapy with conditional approval in both the U.S. and Europe — reduced levels of additional markers…
Seladelpar eases liver damage, itch in primary biliary cholangitis
One year of treatment with Gilead Sciences’ seladelpar normalized biomarkers of liver injury and rapidly reduced itch for most people with primary biliary…
Analyses on volixibat trial data in PSC, PBC slated for June
Interim analyses of data from Phase 2 clinical trials testing Mirum Pharmaceuticals’ oral therapy candidate volixibat in people with itch, or pruritus, due to…
Having PBC may increase risk of IBD, but not vice versa: Study
Primary biliary cholangitis (PBC), a rare autoimmune liver disease, shares 10 genetic risk factors with inflammatory bowel disease (IBD), a group of inflammatory conditions…
New molecule to reduce liver scarring a potential PSC treatment
Researchers at the University of California San Diego (UCSD) have created a molecule, named antisense oligonucleotide (ASO) 56, that is able to potently reduce liver…
Ascletis to stop clinical testing of ASC42 in primary biliary cholangitis
Ascletis Pharma will not to pursue further clinical testing of its experimental oral therapy ASC42 for adults with primary biliary cholangitis (PBC). The…
Elafibranor for PBC may become Genfit’s first approved molecule
Elafibranor, an oral molecule under regulatory review as a new second-line treatment for adults with primary biliary cholangitis (PBC), may become the first candidate…
LB-P8 probiotic on FDA fast track for primary sclerosing cholangitis
The U.S. Food and Drug Administration (FDA) has granted fast track designation to LB-P8, LISCure Biosciences’ experimental live bacterium product that is headed toward…
Phase 1b/2 trial of golexanolone for PBC behavioral symptoms advances
Golexanolone, Umecrine Cognition’s investigational oral therapy, was generally safe and well tolerated in adults with primary biliary cholangitis (PBC) and clinically significant…
Recent Posts
- Abnormal amino acid profile seen in biliary atresia infants after birth
- Our daughter’s PFIC diagnosis made us rethink drinking at Christmas
- Hepatitis D treatment combo granted new designations in US, EU
- Committee recommends seladelpar approval in EU for treating PBC
- Diet rich in omega-3 fatty acids may lower risk of ICP, scientists say